Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M5542 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| M5542 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| M5542 | BIOLOGICAL | Participants will receive a single ascending dose of M5542 subcutaneously on Day 1. |
| Placebo | BIOLOGICAL | Participants will receive a single dose of placebo matched to M5542 subcutaneously on Day 1. |
Inclusion Criteria: * Participants are overtly healthy, as determined by medical evaluation, by physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection, or disease that would pose a risk to participant safety or interfere with the study eval...
M5542 is an investigational monoclonal antibody being developed by Merck KGaA. It is currently in Phase 1 clinical development for use in healthy participants. The drug is being studied in a single ascending dose trial to evaluate its safety and tolerability.
M5542 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being evaluated in a Phase 1 trial in healthy participants to assess its safety and pharmacokinetics.
M5542 is being developed by Merck KGaA, a science and technology company. The company's stock is traded under the ticker MKGAF. The drug is currently in Phase 1 clinical development.
M5542 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial is currently recruiting participants to study single ascending doses of the drug.
M5542 is being studied in a Phase 1 clinical trial with the identifier NCT06577337. This trial is a single ascending dose study in healthy participants, with an enrollment of 49. The trial is recruiting in Germany and is placebo-controlled and double-blinded.
M5542 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied in a clinical trial to evaluate its safety and tolerability in healthy participants.